Clinical Trials /

Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)

NCT02906332

Description:

This is an open-label, Phase II, single center trial of pembrolizumab (MK-3475), lenalidomide and dexamethasone in subjects with high risk Multiple Myeloma (hrMM) post high-dose chemotherapy with autologous stem cell transplantation (ASCT). Patients with high-risk MM defined as those with one of the following abnormalities who have undergone induction therapy followed by single or tandem melphalan -based ASCT will be considered eligible.

Related Conditions:
  • Multiple Myeloma
Recruiting Status:

Active, not recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
  • Official Title: A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma

Clinical Trial IDs

  • ORG STUDY ID: Pro2016-0262
  • NCT ID: NCT02906332

Conditions

  • Multiple Myeloma

Interventions

DrugSynonymsArms
PembrolizumabKeytrudaPembrolizumab + lenalidomide
LenalidomideRevlimidPembrolizumab + lenalidomide
DexamethasoneDecadronPembrolizumab + lenalidomide

Purpose

This is an open-label, Phase II, single center trial of pembrolizumab (MK-3475), lenalidomide and dexamethasone in subjects with high risk Multiple Myeloma (hrMM) post high-dose chemotherapy with autologous stem cell transplantation (ASCT). Patients with high-risk MM defined as those with one of the following abnormalities who have undergone induction therapy followed by single or tandem melphalan -based ASCT will be considered eligible.

Detailed Description

      The primary objectives of this trial are to establish the progression free survival (PFS) of
      ASCT followed by consolidative therapy with pembrolizumab plus lenalidomide and dexamethasone
      and to evaluate the safety of pembrolizumab plus lenalidomide and dexamethasone following
      ASCT. The immunological analysis of cells and cytokines pre and post-therapy will be
      determined from patient bone marrow aspirate and peripheral blood samples as exploratory
      objectives. The overall composition of the gut microbiome will also be determined in patient
      stool samples.

      Patients will be followed by response, EFS/PFS/OS and safety endpoints on an every 3 week
      basis. Bone marrow aspirate specimens will be obtained at screening and at completing of the
      study and peripheral blood specimens will be obtained on a monthly basis to evaluate in
      correlative studies.
    

Trial Arms

NameTypeDescriptionInterventions
Pembrolizumab + lenalidomideExperimentalThis is an open label study. Pembrolizumab 200 mg IV every 3 weeks and lenalidomide 25 mg po daily x 14 days and dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles. This is followed by pembrolizumab 200 mg every 3 weeks and lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for a total of 4 cycles.
  • Pembrolizumab
  • Lenalidomide
  • Dexamethasone

Eligibility Criteria

        Inclusion Criteria:

          -  Be willing and able to provide written informed consent/assent for the trial.

          -  Be 18 years of age on day of signing informed consent.

          -  Has a confirmed diagnosis of MM based on standard criteria. (See Appendix 2 for MM
             Diagnostic Criteria.)

          -  Is between 60 and 180 days from peripheral blood autologous stem cell transplant.

          -  At diagnosis, had MM with measurable disease, defined as:

          -  A monoclonal immunoglobulin spike on serum electrophoresis of at least 0.5 g/dL and/or

          -  Urine monoclonal levels of at least 200 mg/24 hours

          -  For subjects without measurable serum and urine M-protein levels, an abnormal free
             light chain (FLC) ratio (normal value 0.26 - 1.65) with involved FLC ≥10 mg/dL

          -  Radiographic evidence of disease for those without measurable M-spike or free light
             chains.

          -  Has high-risk MM, which must be present at the time of diagnosis, and defined by:

               -  International Staging System (ISS) stage 3 (See Appendix 3 for ISS Staging),
                  and/or

               -  Deletion 13q by cytogenetics, and/or

               -  1q amplification, 1p deletion, p53 deletions (17p deletions), t(4;14), t(14;16),
                  t(14;20), hypodiploidy, and/or

               -  High-risk gene expression profile (GEP) scores

          -  Be able to provide a newly obtained bone marrow aspirate/biopsy material for biomarker
             analysis and disease assessment.

          -  Have a performance status of ≤2 on the ECOG Performance Scale (See Appendix 4).

          -  Demonstrate adequate organ function as defined in Table 1, all screening labs should
             be performed within 28 days of treatment initiation.

          -  All subjects must agree to follow the regional requirements for lenalidomide
             counseling, pregnancy testing, and birth control; and be willing and able to comply
             with the regional requirements (for example, periodic pregnancy tests, safety labs,
             etc.).

          -  Female subjects of childbearing potential should have a negative urine or serum
             pregnancy test within 10-14 days prior to and again within 24 hours prior to receiving
             the first dose of pembrolizumab (MK-3475), lenalidomide and dexamethasone or
             pembrolizumab (MK-3475) and lenalidomide. If the urine test is positive or cannot be
             confirmed as negative, a serum pregnancy test will be required. Female subjects of
             childbearing potential should agree to ongoing pregnancy testing.

          -  Female subjects of childbearing potential must be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study through 120 days after the last dose of study medication (Reference
             Section 4.7.2). Subjects of childbearing potential are those who have not been
             surgically sterilized or have not been free from menses for > 2 years.

          -  Male subjects must agree to use a latex condom during sexual contact with females of
             childbearing potential even if they have had a successful vasectomy starting with the
             first dose of study therapy through 120 days after the last dose of study therapy.

          -  Subject is able to swallow capsules and is able to take or tolerate oral medications
             on a continuous basis.

          -  Male subjects should agree to use an adequate method of contraception starting with
             the first dose of study therapy through 120 days after the last dose of study therapy.

        Exclusion Criteria:

          -  Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigational
             device within 4 weeks of the first dose of treatment.

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial
             treatment. The use of physiologic doses of corticosteroids may be used at the
             investigator's discretion.

          -  Has received an allogeneic stem cell transplant.

          -  Has received any myeloma-directed therapy after ASCT.

          -  Has a known history of active TB (Bacillus Tuberculosis)

          -  Hypersensitivity to pembrolizumab or any of its excipients.

          -  Progressive disease from autologous transplantation at the time of screening

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment and any neurologic symptoms have returned
             to baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for at least 7 days prior to trial treatment. This exception does not include
             carcinomatous meningitis which is excluded regardless of clinical stability.

          -  Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment.

          -  Has known history of, or any evidence of active, non-infectious pneumonitis.

          -  Has an active infection requiring intravenous systemic therapy.

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment.

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.

          -  Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

          -  Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
             [qualitative] is detected).

          -  Has received a live vaccine within 30 days of planned start of study therapy.
      
Maximum Eligible Age:99 Years
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Progression free survival (PFS)
Time Frame:12 Months
Safety Issue:
Description:PFS will be assessed from the date of ASCT, with day 0 defined as date of stem cell infusion (if tandem transplant the 2nd of 2 transplants will be used) until the date of progression, defined as the date at which the patient starts the next line of therapy or the date of death.

Secondary Outcome Measures

Measure:Safety and tolerability of pembrolizumab (MK-3475), lenalidomide and dexamethasone following ASCT.
Time Frame:Adverse events (AEs) assessed every 2 wks on treatment up to 30 days after last dose of study drug. Serious adverse events (SAEs) and events of clinical interest (ECIs) up to 90 days after last dose or start of new anti-cancer therapy, whichever is 1st.
Safety Issue:
Description:Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received pembrolizumab (MK-3475), lenalidomide and dexamethasone, including serious adverse events (SAEs).
Measure:Evaluation of stringent complete response, complete response, and very good partial response rate (sCR + CR + VGPR rate)
Time Frame:Every 3 weeks (day 1 of every 21-day treatment cycle +/- 7 days) through 12 weeks.
Safety Issue:
Description:Assessed by the investigator per International Myeloma Working Group criteria(IMWG) uniform response criteria.
Measure:Time to Progression (TTP)
Time Frame:Time from Day 0 (transplant) and date of enrollment to study completion (through 12 weeks) by investigator assessment.
Safety Issue:
Description:Assessed at 12 months; Subjects without documented PD or death will be censored at the last disease assessment date. Those who died without documented PD will be censored at the time of death.
Measure:Duration of Response (DOR)
Time Frame:Interval between date of first response and date of study completion (through 12 weeks)
Safety Issue:
Description:Assessed by the investigator per International Myeloma Working Group criteria(IMWG) uniform response criteria.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Active, not recruiting
Lead Sponsor:Hackensack Meridian Health

Last Updated